Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30558188 | 0.90 | DPP4 (0.48) | DPP4DPP8DPP9PTGS1GSTK1 | |
| SCHEMBL29376405 | 0.90 | DPP4 (0.48) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL29526133 | 0.88 | DPP4 (0.46) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL31675112 | 0.88 | DPP4 (0.46) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL9853452 | 0.85 | DPP4 (0.51) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL30884812 | 0.85 | DPP4 (0.51) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL30771442 | 0.85 | FOLH1 (0.48) | DPP4DPP8DPP9PTGS1GSTK1 | |
| SCHEMBL537127 | 0.85 | DPP4 (0.61) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL537129 | 0.85 | DPP4 (0.61) | DPP4DPP8DPP9CYP1A2GRM8 | |
| SCHEMBL29531533 | 0.85 | DPP4 (0.61) | DPP4DPP8DPP9CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367315-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | SYNAFFIX BV (NL) | 2025-12-04 | — | — | US | claimed |
| EP-4637831-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | Synaffix B.V. (NL) | 2025-10-29 | — | — | EP | claimed |
| WO-2024133815-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | SYNAFFIX B.V. (NL) | 2024-06-27 | — | — | WO | claimed |
| EP-4389152-A1 | CONJUGATES OF PBD PRODRUGS | Synaffix B.V. (NL) | 2024-06-26 | — | — | EP | claimed |
| EP-4698231-A1 | CLEAVABLE IMMUNE CELL ENGAGERS | Synaffix B.V. (NL) | 2026-02-25 | — | — | EP | disclosed |
| EP-4698280-A1 | STABLE 4-ISOXAZOLINE CONJUGATES | Synaffix B.V. (NL) | 2026-02-25 | — | — | EP | disclosed |
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | SYNAFFIX BV (NL) | 2026-01-22 | — | — | US | disclosed |
| EP-4658318-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | Synaffix B.V. (NL) | 2025-12-10 | — | — | EP | disclosed |
| US-20250367315-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | SYNAFFIX BV (NL) | 2025-12-04 | — | — | US | disclosed |
| EP-4637831-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | Synaffix B.V. (NL) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024218162-A1 | CLEAVABLE IMMUNE CELL ENGAGERS | SYNAFFIX B.V. (NL) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218164-A1 | STABLE 4-ISOXAZOLINE CONJUGATES | SYNAFFIX B.V. (NL) | 2024-10-24 | — | — | WO | disclosed |
| EP-4450489-A1 | STABLE 4-ISOXAZOLINE CONJUGATES | Synaffix B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| EP-4450093-A1 | CLEAVABLE IMMUNE CELL ENGAGERS | Synaffix B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| WO-2024160926-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | SYNAFFIX B.V. (NL) | 2024-08-08 | — | — | WO | disclosed |
| EP-4410313-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | Synaffix B.V. (NL) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024133815-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | SYNAFFIX B.V. (NL) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389152-A1 | CONJUGATES OF PBD PRODRUGS | Synaffix B.V. (NL) | 2024-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021196-A1 | HOMOGENEOUS ANTIBODY-CONJUGATES WITH HIGH PAYLOAD LOADING | FCGR2A, FCGR3B, FCGR1A | DPP4 2684/4885DPP8 2319/4885DPP9 2664/4885 |
| US-20250367315-A1 | ANTIBODY-DRUG CONJUGATES WITH MASKED PBD DIMERS | CD22, PBDC1, PA2G4 | DPP4 1508/4885DPP8 2158/4885DPP9 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.